found that METTL16 plays a procarcinogenic role in HCC, and that eukaryotic translation initiation factor 3 subunit A/B (eIF3a/b) shares potential targets with approximately 50% of METTL16’s targets, indicating methyltransferase structural domain of eIF3a/b as a valuable therapeutic target in cancer treatment (25). Here, EIF3A is linked to hepatocellular carcinoma.